NovMetaPharma Co., Ltd. Stock Price

XKON:A229500 Community·₩144.6b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

A229500 Share Price Performance

₩0

-10500.00 (-100.00%)

₩0

-10500.00 (-100.00%)

₩0

Fri, 3 Apr 26

Share Pricen/a

A229500 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Very low risk with weak fundamentals.

2 Risks

0 Rewards

View Full Analysis

NovMetaPharma Co., Ltd. Key Details

Last Reported Earnings

n/a

Next Reporting Earnings

n/a

: 0
: 0%
: 0%
: 0%

View Full Analysis

About A229500

Founded: 2010
Employees: n/a
CEO: Sun-Wook Hwang
WebsiteView website: www.novmeta.com

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea.